ArticleACS omega2026
Analytical Validation of an HPLC-DAD Method for Ivermectin Quantification in Polymeric Nanocapsules.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin (IVM) is a broad-spectrum antiparasitic drug whose clinical application is limited by poor aqueous solubility, chemical instability, and pharmacokinetic variability. Polymeric nanocapsules represent a promising strategy to overcome these limitations. However, their complex composition requires reliable and selective analytical methods for accurate drug quantification. In this study, a reversed-phase HPLC-DAD method was developed and validated for the quantification of ivermectin and applied to polymeric nanocapsules, including the determination of encapsulation efficiency and drug loading. Chromatographic separation was achieved on a C18 column using isocratic elution with acetonitrile and purified water (90:10, v/v) with diode-array detection at 253 nm and a retention time of approximately 4.7 min. The method was validated according to ICH Q2-(R2) guidelines, demonstrating adequate selectivity through evaluation of matrix interference and analysis under stress conditions. Linearity was observed over the analytical range (R
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.